Karen A. Dawes, Director at REPLIGEN CORP (RGEN), sold 9,170 shares at $200.01 ($1.9M) on 2021-07-20, disclosed to the SEC on 2021-07-22.
Open-market sale of $1.9M RGEN by Director. Not flagged as scheduled, tax-driven, or recurring — but no specific bearish signal from our filters. Reasons for insider sales vary widely.
Nothing distinguishes this filing.
| # | Price | Shares | Value | % of Total |
|---|---|---|---|---|
| 1 | $200.01 | 288 | $58K | 3.1% |
| 2 | $200.01 | 288 | $58K | 3.1% |
| 3 | $201.37 | 806 | $162K | 8.8% |
| 4 | $201.37 | 806 | $162K | 8.8% |
| 5 | $202.29 | 2,877 | $582K | 31.4% |
| 6 | $202.29 | 2,877 |
| $582K |
| 31.4% |
| 7 | $203.11 | 614 | $125K | 6.7% |
| 8 | $203.11 | 614 | $125K | 6.7% |
| Total | $202.09 avg | 9,170 | $1.9M | 100% |
| Filing → |
| RGEN | SELL | 2023-08-30 | $146K | — | Filing → |
| RGEN | SELL | 2022-09-09 | $352K | — | Filing → |
| RGEN | SELL | 2022-05-26 | $4.4M | — | Filing → |